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Abstract
Bioprosthetic leaflets made from animal tissues are used in the majority of surgical and transcatheter cardiac valve replacements.
This study develops a new surgical bioprosthesis, using porcine pericardial leaflets. Porcine pericardium was obtained from
genetically engineered pigs with a mutation in the GGTA-1 gene (GTKO) and fixed in 0.6% glutaraldehyde, and used to develop
a new surgical valve design. The valves underwent in vitro hydrodynamic test in a pulse duplicator and high-cycled accelerated
wear testing and were evaluated for acute haemodynamics and thrombogenicity in a juvenile sheep implant study for 48 h. The
porcine surgical pericardial heart valves (pSPHVs) exhibited excellent hydrodynamics and reached 200 million cycles of in vitro
durability, with no observable damage. Juvenile sheep implants demonstrated normal valve function with no acute thrombogenic
response for either material. The pSPHV incorporates a minimalistic construction method using a tissue-to-tissue design to cover
the stent. This new design is a proof of concept alternative to the use of bovine pericardium and synthetic fabric in surgical
bioprosthetic heart valves.
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Abbreviations
AWT Accelerated wear test
BHV Bioprosthetic heart valve
CO Cardiac output
EOA Effective orifice area
GGTA-1 Alpha-1,3-galactosyltransferase
GLP Good laboratory practice
GTKO α-Galactosyltransferase knockout
ISO International Standard Organization
MHV Mechanical heart valve
pSPHV Porcine surgical pericardial heart valve
SVD Structural valve degeneration
TAVI Transcatheter aortic valve implantation
Introduction
Surgical bioprosthetic heart valves (BHVs) have been the gold
standard treatment for patients suffering from severe cardiac
valve diseases. Contrary to mechanical heart valves (MHVs),
BHVs do not require long-term anticoagulation therapy which
is associated with high risk of thromboembolic complications
and haemorrhage [1]. BHVs have been an effective therapy in
older patients for decades, but are prone to age-dependent
structural valve degeneration (SVD) and limited durability in
patients younger than 60 years old. SVD is associated with
leaflet calcification, fibrosis, and tearing [2, 3] which lead to
irreversible valve deterioration and haemodynamic disruption
[4]. Despite these limitations, the use of BHVs is increasing
compared with MHVs [5–9].
BHVs have been typ i c a l l y made by sewing
glutaraldehyde-fixed bovine pericardium or porcine aortic
valve tissue on a fabric covered polymeric or metal stent.
The choice of either bovine pericardium or porcine valve
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leaflets to construct BHV leaflets had remained unchanged
until the introduction of percutaneous transcatheter aortic
valve implantation (TAVI) in the early 2000s. The original
Cribier designed percutaneous heart valve device utilised
equine pericardium for the valve leaflet material.
Subsequently, the Cribier-Edwards valve was re-engineered
with bovine pericardial leaflets for a first in man study [10].
The use of porcine pericardium as heart valve leaflet mate-
rial is currently limited to percutaneously implantable valves,
where its relatively low thickness is advantageous, helping
reduce the delivery system profile. Porcine pericardial leaflet
has been exploited by the Medtronic CoreValve and
CoreValve Evolut™ R [11], Boston Scientific ACURATE
neo™ [12, 13], Abbott Portico™ [14], JenaValve™ [15],
and Colibri heart valve (dry porcine pericardium) [16].
Although there is no clinically adopted surgical BHV with
porcine pericardial leaflets, the success of porcine pericardial
leaflet in TAVI devices, at least for midterm durability, sug-
gests that under the right conditions there is no inherent bio-
physical prohibition to using this material for heart valve leaf-
let, even in a surgical BHV. Direct biophysical comparisons
between porcine and bovine pericardium have been reported
[17] and show that porcine pericardium is thinner, stiffer, and
less extensible compared with adult or calf bovine pericardi-
um, but maintains similar ultimate tensile strength. The use of
thinner leaflet materials in a surgical replacement heart valve,
if durable, would be expected to increase the effective orifice
area and improve hydrodynamic function.
There is growing interest in using Gal-free porcine tissue as
BHV material because elimination of the Gal antigen may
reduce antibody associated BHV calcification, especially in
younger patients [18–22]. We have previously reported bio-
chemical and physical equivalence of glutaraldehyde-fixed
porcine pericardium derived from standard pigs and from pigs
with an engineered mutation in the GGTA1 gene to block
expression of the galactose α 1,3 galactose (Gal) antigen
(GTKO pigs) [23]. Both types of glutaraldehyde-fixed peri-
cardium demonstrated the same general morphology and col-
lagen content and no significant differences in uniaxial stress
or suture retention testing. In this paper, we describe and eval-
uate the design of a new porcine surgical pericardial heart
valve (pSPHV) and test its hydrodynamics and in vitro dura-
bility.We also perform an acute, 48 h, in vivo study in juvenile
sheep to assess the valve function and thrombogenicity.
Methods
Pig Tissue Processing and Fixation
Standard pig tissue was obtained from a local abattoir.
Genetically modified GGTA-1 deficient (GTKO) pigs were
bred and raised in accordance with the Animals (Scientific
Procedures) Act of 1986, published by the UK Home
Office, and the Guide for the Care and Use of Laboratory
Animals from the US National Institute of Health
(Publication No. 85-23, revised 1996). Heart lung blocks were
collected from pigs, chilled on ice, and promptly shipped for
processing. On receipt, the tissues were rinsed in water and
dissected to recover the pericardial sac. The pericardium was
rinsed in sterile saline, split, grossly cleared of fat, trimmed,
washed thoroughly in sterile saline, and stored overnight at
4 °C. The pericardium was subsequently carefully cleaned of
fat and fixed in 0.6% glutaraldehyde in 20 mMHEPES-Saline
(pH 7.4) containing 13mMMgCl2-H2O for 24 h at 4 °C. After
fixation, tissues were rinsed in sterile saline and stored in
fixation buffer containing 0.2% glutaraldehyde at 4 °C until
used.
Valve Construction
The construction technique adopted a new approach [24]
where the pSPHV is formed with three leaflets from a single
continuous strip of pericardium, attached to a second pericar-
dial layer which wraps around a Delrin stent of 25mm internal
diameter and 1.2 mm of wall thickness (Fig. 1). Pericardial
tissues were quality controlled by measuring and recording
the thickness distribution of the glutaraldehyde-fixed patches
using a Mitutoyo thickness gauge. Tissue fibre density and
orientation were mapped by observation on a viewbox.
Pericardial patches for leaflet constructionwere selected based
on this visual assessment and the tissue thickness. Pericardium
covering the stent was similarly selected for homogeneity and
the absence of visual defects. The pSPHV was constructed by
superposing and fixing together the two layers of pericardium
by automate sewing of a serrated suture line defining the tri-
leaflets profile (Fig. 1a). The two pericardial layers were rolled
and closed on the side to form a tubular assembly, which was
then mounted on the stent. The support pericardial layer was
cut, wrapped around the stent posts, and sewn to the down-
stream edge of the same pericardial layer to fully cover the
valve stent [25] (Fig. 1b). No leaflet pressure fixation was
used during the construction process. One pSPHV was pre-
pared for the purpose of in vitro assessment. Two GTKO
pSPHVs were constructed for acute evaluation in a juvenile
sheep model.
In Vitro Hydrodynamic Assessment
The in vitro hydrodynamic performance of the valve was
evaluated using a commercial hydromechanical pulse dupli-
cator (Vivitro Superpump System SP3891, Vivitro, Victoria,
BC, Canada), reproducing physiologically equivalent aortic
pressures and flows, in conformity to the international stan-
dard ISO5840 requirements [26]. The valve was mounted on
the aortic test chamber and tested at increasing cardiac outputs
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(COs) of 2, 3, 4, 5, 6, and 7 l/min, with a mean arterial pressure
of 100 mmHg, a fixed heart rate of 70 beats per minute, and
systole occupying 35% of the cardiac cycle. Testing fluid was
a 37 °C buffered saline solution (0.90% w/v NaCl).
Under stabile mean arterial pressure and the cardiac
output flow, measurements of atrial, ventricular, and aor-
tic pressures and aortic flow were collected during 10
consecutive cardiac cycles, using the ViViTest software.
Based on these recordings, the mean transvalvular systolic
pressure drop (ΔP), the total regurgitant volume, and the
regurgitant fraction were calculated. The total regurgitant
volume includes the closing regurgitant volume, associat-
ed with the dynamic of valve closure, and the leakage
regurgitant volume, corresponding to the leakage through
the closed valve. The total regurgitant fraction represents
the regurgitant volume expressed as a percentage of the
stroke volume. Effective orifice area (EOA), which repre-
sents the minimal cross-sectional area of the downstream
jet emerging from aortic valve orifice [27], was derived
from the continuity equation, applying Gorlin’s formula
[28].
Accelerated Wear Test
The functional durability of the valve design was evaluated in
an in vitro accelerated wear test (AWT) setup, using a VDT-
3600i AWTsystem (BDC Laboratories, CO, USA). The valve
was mounted on a test chamber, with 37 ± 1 °C buffered saline
with 1 g/l of sodium azide testing fluid as a fungicide and
bactericide, running at 10 Hz cycle rate, set to maintain a peak
differential pressure above 100 mmHg across the closed valve
for at least 5% of each cycle [26]. The system software pro-
vides continual monitoring of the real-time differential pres-
sures, recording only the cycles where pressure conditions
complied with the specified testing requirements. The test
was initially run for 200 million cycles, as requested by the
ISO5840 standard for flexible leaflet heart valve substitutes.
The valve was visually inspected for any signs of damage on
daily basis during working days, and functionally evaluated in
the pulse duplicator before and after completing the 200 mil-
lion cycles.
Acute Animal Evaluation
Valves GTKO pericardium based on the pSPHV design
(n = 2) were implanted in female juvenile sheep for
48 h, in the orthotopic mitral position. The implants
were performed at a GLP-compliant preclinical research
centre, Institut Mutualiste Montsouris Recherche
(IMMR, Paris, France), in accordance with the
Animals (Scientific Procedures) Act 1986. Post-implant
transthoracic echocardiography was performed to assess
the valve haemodynamics. At explant (48 h), the ani-
mals were sacrificed humanely by intravenous overdose
of barbiturate, and the heart was explanted and
dissected.
Results
The pSPHV was successfully manufactured, with an av-
erage leaflet thickness of 0.35 ± 0.4 mm and a pericardial
stent covering of 1.8 ± 0.1 mm thickness (Fig. 2). The
valve was assessed for its hydrodynamic function prior
to undergoing high-cycled AWT. As the cardiac output
in the pulse duplicator increased from 2 to 7 l/min, the
valve demonstrated a systolic pressure drop rising from
Fig. 2 GTKO porcine pericardial bioprosthesis, top row: newly made
before undergoing AWT, and bottom row: after 200 million cycles of
AWT. Post-AWT, the pericardium was slightly discoloured, with no
visible damage, and the leaflets were deformed into a trifoil shapes (as
happens following pericardium pressure fixation). The serrated leaflet
suture line is visible in red colour
Fig. 1 Schematic diagram of a the arrangement of pericardial layers and leaflets suture line, and b construction steps used for the new bioprosthetic heart
valve, demonstrating the pericardial leaflets (1); pericardial wrapping layer (2); leaflet suture line (3); Delrin valve frame (4)
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2.32 ± 0.05 to 6.00 ± 0.16 mmHg and an effective orifice
area enlarging from 2.44 ± 0.02 to 5.43 ± 0.06 cm2. The
regurgitant fraction was stable below 6% up to 5 l/min,
then linearly increased to 12.71 ± 2.70% at 7 l/min (solid
lines in Fig. 3).
AWT was used to assess the durability of the pSPHV.
At a pulse frequency of 10 Hz, the valve remained stable,
maintaining the set peak differential pressure of ≥
100 mmHg across the closed valve for at least 5% of each
cycle, as prescribed by the international standard ISO5840
[26]. After completing 200 million cycles, the valve was
removed from the AWT rig and showed no sign of struc-
tural damage at visual inspection. The hydrodynamic per-
formance of the pSPHV demonstrated a comparable pre-
and post-AWT pressure drops at cardiac outputs up to 6 l/
min. The post-AWT pressure drop was higher (10.21 ±
0.24 mmHg) at 7 l/min. The effective orifice area was
maintained in the range from 3.35 ± 0.05 to 4.67 ±
0.03 cm2 at different output conditions. The regurgitant
fraction was reduced significantly and remained below
4.39 ± 2.17 throughout all cardiac outputs (dashed lines
in Fig. 3).
The pSPHVs were successfully implanted in the
ovine model. Continuous wave Doppler examination im-
mediately after implantation and prior to explant showed
good haemodynamics with low transvalvular gradients.
The valves displayed full opening of the leaflets with
laminar flow through a wide orifice area (Fig. 4a, b),
and full coaptation and competence of the leaflets dur-
ing systole, with no measurable leakage (Fig. 4c, d).
The mean transvalvular pressure gradient measured as
3 mmHg, reaching a maximum of 6 mmHg. The mean
and maximum jet velocities were measured as 74.0 and
122 cm/s, respectively. The velocity integral was
19.8 cm. On explant, there was no evidence of valve
induced thrombosis.
Discussion
In this study, we investigated a new surgical bioposthetic
valve design using porcine pericardium as the leaflet material.
The leaflets were formed from a single patch of pericardium,
attached to a second pericardial layer (support layer) to con-
nect the leaflets to the frame (Fig. 1). This approachminimises
the overall valve profile by allowing the entire inner and outer
surfaces of the valve, including the sewing cuff, to be covered
by no more than a single layer of pericardium. It also provides
tissue-to-tissue contact of the pericardial leaflets to the
pericardial-covered frame, minimising the risk of leaflet abra-
sion and related structural deterioration. The in vitro hydrody-
namic performance of the pSPHV met and exceeded the min-
imum requirements of ISO5840 for both aortic and mitral
applications. The ISO standard specifies the performance re-
quirements, as a function of valve size, in terms of minimum
EOA and maximum regurgitant fraction achieved at a CO of
5 l/min [26]. Assuming a supra-annular implant position, the
valve would be suitable for a tissue annulus of 25 mm, requir-
ing a minimum EOA larger than 1.45 cm2, and a regurgitant
fraction below 15%. In the case of an intra-annular implanta-
tion, the most suitable tissue annulus diameter would be of
28mm, which is not specified in the standard. Considering the
more conservative implantation size of 29 mm, the minimum
required EOA is equal to 1.95 cm2, and the maximum toler-
ated regurgitant fraction is of 20%. This sets a range of EOA
(1.45–1.95 cm2) and regurgitant fraction (15–20%) for the
minimal performance standard of the pSPHV. At a cardiac
output of 5 l/min, the pSPHV design shows an EOA of 4.83
± 0.10 and 3.72 ± 0.0 cm2, pre- and post-AWT, and a
regurgitant fraction of 4.72 ± 1.52 and 1.78 ± 1.41% pre- and
post-AWT, respectively. The pSPHV demonstrated similar
pressure drops pre- and post-AWT when tested in the pulse
duplicator setup. The unusually higher peak of 10.21 ±
0.24 mmHg at 7 l/min post-AWT is likely to be due to leaflet
Fig. 3 Hydrodynamic test parameters evaluated over increasing cardiac
output. Left: aortic pressure gradient (ΔP), centre: effective orifice area
(EOA), right: percent regurgitant fraction. Data are presented as means ±
standard deviation. Solid black lines represent the valve performance
prior to undergoing high-cycled AWT, and dashed grey lines represent
the data after 200 million cycles of AWT
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fluttering. This is a common phenomenon with bioprosthetic
heart valves, often reported at high COs [29] and can result in
some loss in the valve efficiency. These excellent hydrody-
namics were similarly maintained across all tested cardiac
outputs (Fig. 3). The pSPHV investigated in this study was
durable and successfully passed 200 million cycles of AWT,
equivalent to 5 years of normotensive function, as per the
international standard [26]. Preliminary studies in juvenile
sheep demonstrate that this valve design had normal haemo-
dynamic function (Fig. 4).
While porcine pericardium is used in transcatheter valve
designs, including Medtronic CoreValve, Boston Scientific
ACURATE neo™, Abbott Portico™, JenaValve™, and
Colibri heart valve [11–16], this is the first instance we are
aware of using porcine pericardium as leaflet material in a du-
rable surgical heart valve design. Current surgical BHVs made
from porcine valve leaflets or bovine pericardium typically
have a multi-layered structure with several layers of biocompat-
ible textile and biological tissue sutured to one another. Intricate
suturing of multiple layers is a more expensive construction
method and may lead to an increase in potential failure points
on the implant [30]. Furthermore, having multiple fabric/
pericardial layers can compromise the valve’s hydrodynamic
performance, as the additional layers tend to reduce the internal
diameter of valve, narrowing its orifice area and increasing the
resultant transvalvular pressure drop for a given nominal size
[31]. Porcine pericardial leaflets, being 30–40% thinner than
their bovine counterparts, allow for valves with more flexible
leaflets which can attain wider orifice areas, thus improving
haemodynamics. The use of porcine pericardium is largely con-
fined to applications which benefit from the smaller thickness
such asminimally invasive BHVreplacement and percutaneous
bioprostheses. In fact, the reduction in prosthetic profile and
crimp diameter enabled by the thinner tissue represent a major
Fig. 4 Echo-Doppler images illustrating the haemodynamics performances of GTKO pSVHV showing a, b full opening and laminar flow through the
leaflets and c, d full coaptation and competence of the leaflets
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advantage, simplifying advancement of the catheter through
smaller arteries and reducing the associated risk of vascular
complication. Currently, a number of transcatheter valves, such
as the CoreValve System byMedtronic (Minneapolis, MN) and
the ACURATE neo valve by Boston Scientific (Marlborough,
MA), employ porcine pericardial leaflets as an alternative to
bovine pericardium. These devices have shown a successful
midterm outcome in inoperable and high-risk patients, when
compared with surgical bioprosthesis [32–36]. Although the
thinner porcine pericardial tissue is necessarily structurally
weaker than its bovine alternative, this study suggests that a
durable surgical heart valve using porcine pericardial leaflets
can also be produced.
There is growing interest in using Gal-free animal tissues
from Gal-knockout pigs (GTKO) to reduce anti-Gal antibody-
associated tissue calcification [18, 21, 22, 37, 38]. While the
potential advantage of Gal-free tissue has not been clinically
demonstrated, our previous studies have shown that
glutaraldehyde-fixed GTKO and standard porcine pericardial
tissues have same general morphology, collagen content, and
mechanical strength [23]. In this study, we showed that the new
pSPHV design made with GTKO pericardium exhibited nor-
mal haemodynamic function and no evidence of unusual
thrombogenicity in an acute, 48 h, juvenile sheep study.
Further long-term animal studies are required to establish equal
biological function. This study was limited by the number of
available valves. A more detailed investigation using this same
valve design, but with larger sample number, is currently ongo-
ing to further evaluate the hydrodynamic performance and du-
rability, and to compare the in vivo biological performance and
safety of valves made from standard and GTKO pericardium.
The current study suggests that porcine pericardium has ade-
quate structural strength to be used as surgical BHV leaflets
material, in the context of a valve design which incorporates a
minimal overall valve profile and tissue-to-tissue contact of the
pericardial leaflets to the pericardial-covered frame. The new
pSPHV design developed in this study was durable and showed
excellent haemodynamics, supporting the feasibility of using
thinner leaflet materials in surgical heart valves.
Conclusion
A novel surgical bioprosthesis using porcine pericardial leaf-
lets, an improved design and a refined construction technique,
was developed and assessed. The new minimalistic construc-
tion method allows for making a bioprosthesis with smaller
profile, and thinner leaflets, which can be durable reaching
200 million cycles of AWT with no visible damage, and ex-
hibits excellent hydrodynamics. These encouraging results
suggest that durable surgical valves with improved hydrody-
namics can be produced using thinner porcine pericardial
leaflets.
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